The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Intercept Pharmaceuticals's share price is $12.11.
Intercept Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $8.16. Hence, Intercept Pharmaceuticals's PS Ratio for today is 1.48.
The historical rank and industry rank for Intercept Pharmaceuticals's PS Ratio or its related term are showing as below:
ICPT'
s PS Ratio Range Over the Past 10 Years
Min: 1.26 Med: 17.77 Max: 5136.22
Current: 1.46
During the past 13 years, Intercept Pharmaceuticals's highest PS Ratio was 5136.22. The lowest was 1.26. And the median was 17.77.
ICPT's PS Ratio is ranked better than 90.35% of 1005
companies
in the Biotechnology industry
Industry Median: 10.08
vs ICPT: 1.46
Intercept Pharmaceuticals's Revenue per Sharefor the
three
months ended in Mar. 2023 was $1.63.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $8.16.
Warning Sign:
Intercept Pharmaceuticals Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of Intercept Pharmaceuticals was -3.60% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 2.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 9.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 67.90% per year.
During the past 13 years, Intercept Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 296.30% per year. The lowest was -46.30% per year. And the median was 10.70% per year.
Back to Basics: PS Ratio
Intercept Pharmaceuticals PS Ratio Historical Data
The historical data trend for Intercept Pharmaceuticals's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Intercept Pharmaceuticals Annual Data
Trend
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
PS Ratio
15.96
15.57
3.48
1.99
1.46
Intercept Pharmaceuticals Quarterly Data
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
PS Ratio
1.92
1.56
1.55
1.46
1.65
Competitive Comparison
For the Biotechnology subindustry, Intercept Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intercept Pharmaceuticals PS Ratio Distribution
For the Biotechnology industry and Healthcare sector, Intercept Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Intercept Pharmaceuticals's PS Ratio falls in comparison to its industry or sector. The grey bar indicates the PS Ratio's extreme value range as defined by GuruFocus.
Intercept Pharmaceuticals PS Ratio Calculation
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Intercept Pharmaceuticals's PS Ratio for today is calculated as
Intercept Pharmaceuticals's Share Price of today is $12.11.
Intercept Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.16.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Intercept Pharmaceuticals (NAS:ICPT) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Intercept Pharmaceuticals PS Ratio Related Terms
Thank you for viewing the detailed overview of Intercept Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Intercept Pharmaceuticals (NAS:ICPT) Business Description
Intercept Pharmaceuticals is a biotech company focused on developing and commercializing novel therapeutics to treat chronic liver diseases. Obeticholic acid, or OCA, is an agonist of the farnesoid X receptor. OCA was approved as Ocaliva to treat primary biliary cirrhosis in 2016 and is being developed for a variety of chronic liver diseases, including nonalcoholic steatohepatitis, or NASH.
Create New Portfolio
Portfolio Contest
Personalize
Premium Gurus 
0.14(1.14%) Volume: 170,420 10:55AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
ICPT has been successfully added to your 
